
- A Diversified Portfolio with Global Vision
- Patient-centric focus is integral to Biosion’s R&D strategy
- Portfolio of differentiated biologics to compete on the global stage
Biosion is committed to developing therapies that will have significant impact in treating patients worldwide with immune and oncologic diseases.
Our best-in-class and first-in-class portfolio is designed to address significant unmet medical needs through the development of mono and bi-specific protein therapeutics, antibody drug conjugates and macrophage reprogramming agents
Biosion is committed to developing therapies that will have significant impact in treating patients worldwide with immune and oncologic diseases.
Our best-in-class and first-in-class portfolio is designed to address significant unmet medical needs through the development of mono and bi-specific protein therapeutics, antibody drug conjugates and macrophage reprogramming agents